Pacer Advisors Inc. maintains a significant stock position in
Labcorp Holdings, at $87.77 million. The company has, however, been reassessing its valuation after adjusting its growth outlook for its contract research unit. Despite the slowdown, Labcorp's push into oncology could be a potential game-changer, bolstered by solid total returns and steady share price appreciation. Several institutions, like Osaic Holdings Inc. and Bellevue Group AG, increased their holdings in Labcorp while others, such as Wedge Capital Management, sold their shares. Additionally, Labcorp's Q3 earnings exceeded expectations, and its net margin surged to 6.2%. The successful acquisition of select assets of BioReference Health's innovative oncology and clinical testing services businesses also underscores Labcorp's strategic growth. The company recently launched an FDA-cleared Alzheimer's diagnostic blood test nationwide and unveiled an AI tool to streamline lab test selection. A newly appointed board member, Victor Bulto, adds to Labcorp's leadership strength. Underscoring a successful trend, Labcorp's stock hit a 52-week high, benefiting long-term investors. Nonetheless, reduced growth and margin pressures are concerns shareholders should pay attention to.
Laboratory Corporation of America Holdings LH News Analytics from Tue, 11 Mar 2025 07:00:00 GMT to Fri, 26 Dec 2025 12:03:57 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor 1
